Cargando…

Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study

BACKGROUND: Rifaximin has been shown to reduce the incidence of hepatic encephalopathy and other complications in patients with cirrhosis. However, few studies have investigated the effect of rifaximin in cirrhotic patients with refractory ascites. AIM: To evaluate the effects of rifaximin in the tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Xin-Yue, Ding, Hui-Guo, Zheng, Jun-Fu, Fan, Chun-Lei, Li, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Observational Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962437/ https://www.ncbi.nlm.nih.gov/pubmed/31988585 http://dx.doi.org/10.3748/wjg.v26.i2.199

Ejemplares similares

Six-minute walking test performance is associated with survival in cirrhotic patients
por: Pimentel, Carolina Frade M G, et al.
Publicado: (2021)

Prevalence and risk factors of lymphatic dysfunction in cirrhosis patients with refractory ascites: An often unconsidered mechanism
por: Arya, Rahul, et al.
Publicado: (2023)

Outpatient telephonic transitional care after hospital discharge improves survival in cirrhotic patients
por: Rao, Bhavana Bhagya, et al.
Publicado: (2019)

Management of refractory cirrhotic ascites: challenges and solutions
por: Fukui, Hiroshi, et al.
Publicado: (2018)

Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
por: Wang, Shuzhen, et al.
Publicado: (2018)

Effectiveness of Angiotensin II for Catecholamine Refractory Septic or Distributive Shock on Mortality: A Propensity Score Weighted Analysis of Real-World Experience in the Medical ICU
por: Quan, Michele, et al.
Publicado: (2022)

Natural history of covert hepatic encephalopathy: An observational study of 366 cirrhotic patients
por: Wang, An-Jiang, et al.
Publicado: (2017)

Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis
por: Kukla, Michał, et al.
Publicado: (2017)

Competing risk analysis on outcome after hepatic resection of hepatocellular carcinoma in cirrhotic patients
por: Cucchetti, Alessandro, et al.
Publicado: (2017)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Toll-like receptor 4 polymorphisms and bacterial infections in patients with cirrhosis and ascites
por: Alvarado-Tapias, Edilmar, et al.
Publicado: (2018)

The Palliative Management of Refractory Cirrhotic Ascites Using the PleurX(©) Catheter
por: Reinglas, Jason, et al.
Publicado: (2016)

Consensus care recommendations for alfapump(®) in cirrhotic patients with refractory or recurrent ascites
por: Aagaard, Niels Kristian, et al.
Publicado: (2022)

Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results
por: Teich, Niels, et al.
Publicado: (2020)

Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes
por: Stapff, Manfred Paul
Publicado: (2018)

Emergence of rifampin-resistant staphylococci after rifaximin administration in cirrhotic patients
por: Chang, Ji Young, et al.
Publicado: (2017)

Development and predictive validity of the cirrhosis-associated ascites symptom scale: A cohort study of 103 patients
por: Riedel, Agnete Nordheim, et al.
Publicado: (2018)

Serum vascular endothelial growth factor as a tumor marker for hepatocellular carcinoma in hepatitis C virus-related cirrhotic patients
por: Alzamzamy, Ahmed, et al.
Publicado: (2021)

Splanchnic and Systemic Hemodynamics in Cirrhotic Patients With Refractory Ascites. Effect of Peritoneovenous Shunting
por: Vons, Corinne, et al.
Publicado: (1991)

SGLT2 Inhibitors: A New Dawn for Recurrent/Refractory Cirrhotic Ascites
por: Gao, Yuan, et al.
Publicado: (2021)

Real-world data on the infliximab biosimilar CT-P13 (Remsima(®)) in inflammatory bowel disease
por: Huguet, Jose María, et al.
Publicado: (2021)

Surgical Treatment of Cirrhotic Ascites
Publicado: (1927)

Ayurvedic management of cirrhotic ascites
por: Aswathy, G., et al.
Publicado: (2016)

Low-radiation and high image quality coronary computed tomography angiography in “real-world” unselected patients
por: Richards, Caryl Elizabeth, et al.
Publicado: (2018)

Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China
por: Shi, Ji-Hao, et al.
Publicado: (2020)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study
por: González-Montero, Jaime, et al.
Publicado: (2023)

Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites
por: Huang, Lin-Lin, et al.
Publicado: (2014)

Proximal Splenic Artery Embolization to Treat Refractory Ascites in a Patient With Cirrhosis
por: Caporali, Cristian, et al.
Publicado: (2021)

Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections
por: Sun, Hsin-Yun, et al.
Publicado: (2022)

Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting
por: Ramos, Huascar, et al.
Publicado: (2017)

Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil
por: Zaltman, Cyrla, et al.
Publicado: (2021)

Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation
por: Abrignani, Maurizio Giuseppe, et al.
Publicado: (2022)

Contributory roles of sarcopenia and myosteatosis in development of overt hepatic encephalopathy and mortality after transjugular intrahepatic portosystemic shunt
por: Yin, Liang, et al.
Publicado: (2023)

International normalized ratio and Model for End-stage Liver Disease score predict short-term outcome in cirrhotic patients after the resolution of hepatic encephalopathy
por: Hu, Xiao-Peng, et al.
Publicado: (2019)

Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results
por: Bichoupan, Kian, et al.
Publicado: (2017)

Novel roles of lipopolysaccharide and TLR4/NF-κB signaling pathway in inflammatory response to liver injury in Budd-Chiari syndrome
por: Li, Jie, et al.
Publicado: (2021)

Impact of Rifaximin on the Frequency and Characteristics of Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis and Ascites
por: Lutz, Philipp, et al.
Publicado: (2014)

Correlation of pressure gradient in three hepatic veins with portal pressure gradient
por: Wang, Hao-Yu, et al.
Publicado: (2022)

Comment on ‘Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites’
por: Ahmed, Furqan
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_agb3i4gk8ig2h5n4j9ul4bnt88